Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Merck

Paychex

Rollins

Schwab US Dividend Equity ETF

Snap-on

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 1.84% in May, outperforming the S&P 500 by 1.40%. Year-to-date the portfolio is up 6.66% and trailing the S&P 500 by 2.99%. Since inception, the portfolio is generating alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Passively Outpacing The Market

CVS Health

Teva Pharmaceutical

Walgreens

New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance Inc. WBA, -0.68%, and with drug makers Teva Pharmaceutical Industries Ltd. TEVA, -0.61% and AbbVie Inc.'s ABBV, +0.61% Allergan.

NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in CLL Six-year median follow-up from the Phase 3 CLL14 study shows continued PFS after treatment with venetoclax plus obinutuzumab compared to treatment with chlorambucil plus obinutuzumab in previously untreated patients with CLL and co-existing conditions Final seven-year follow-up results of the Phase 3 MURANO trial demonstrate sustained PFS and overall survival (OS) with venetoclax and rituximab compared to bendamustine and rituximab in patients with relapsed/refractory (R/R) CLL NORTH CHICAGO, Ill. , June 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new findings demonstrating sustained long-term safety and efficacy of VENCLYXTO®/ VENCLEXTA® (venetoclax)-based combination therapies in patients with previously untreated CLL with co-existing conditions, as well as R/R CLL.

AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients

Amcor Plc

Franklin Resources

Cincinnati Financial

Chevron

Federal Realty Investment Trust

NextEra Energy

Realty Income Corp

Target

T. Rowe Price Group

V.F.

Exxon Mobil

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 67 Aristocrats, screened as of June 6, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 20.58%-43.58% topped-by TGT & VFC. By yield, VFC topped-all Aristocrats. Top-ten Yields from TROW, ABBV, FRT, BEN, AMCR, IBM, O, WBA, MMM, & VFC, averaged 5.15%.

4 Dividend Aristocrat Buys For June And 5 To Watch

Amgen

Exclusivity losses can be big setbacks for pharma companies. AbbVie and Amgen both face this key overhang.

Is AbbVie or Amgen the Better Bargain Buy Right Now?

Citigroup

Caterpillar

Citizens & Northern

General Dynamics

Haleon PLC

Kinder Morgan

Norfolk Southern

Norwood Financial

Healthpeak Properties

Premier Financial

Provident Financial Services

Procter & Gamble

Starbucks

AT&T

Texas Instruments

Verizon

WestRock

The author's May dividend income reached $883, a 20.25% increase compared to May 2022. Banks contributed 22.4% of the May dividend income, with a total of $198.05. The AT&T dividend cut in 2021 still impacts the author's dividend income, preventing them from crossing the $1,000 mark.

Bert's May 2023 Dividend Income Summary

NORTH CHICAGO, Ill. , June 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023.

AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

AbbVie Inc.'s share price has been slipping as its globally best-selling drug Humira has lost its U.S. patent protection. At least 8 biosimilar versions of the drug will be launched by rival companies this year - Humira sales will likely decline by ~30% year-on-year, and ~25% thereafter. Slightly underwhelming Q1 2023 earnings have also affected ABBV stock's valuation - but shareholders should not panic.

AbbVie Stock May Be Falling On Humira LOE - But Investors Shouldn't Panic

Arrow Financial

Community Trust Bancorp

Enbridge

Essex Property Trust

KFA Mount Lucas Index Strategy ETF

Altria

Philip Morris

The NY Fed estimates a 68% recession probability within the next 12 months, the highest risk in 42 years. Dividend aristocrats can provide a relatively safe investment option during a recession, with a history of raising dividends through economic downturns and much lower volatility. A diversified high-yield portfolio of dividend aristocrats can offer market-like returns with lower volatility and higher yield.

10 Dividend Aristocrats For The Ultimate 6% Yielding Retirement Portfolio

Genuine Parts

Kimberly-Clark

Coca-Cola

Walmart

With the debt ceiling issue once again kicked down the proverbial road, investors can focus on what the upcoming summer months will have to offer, and it may not be pretty.

The Narrow Rally Likely Is Almost Over: 7 ‘Strong Buy' Safe-Haven Dividend Kings to Buy Now

Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year.

Why AbbVie and Amgen Are Moving Lower Today

CME Group

Canadian Pacific Kansas City Limited

My dividend growth portfolio consists of 22 individual stocks in eight sectors, with a focus on industries with high entry barriers and dominant positions in supply chains. The portfolio has delivered solid returns, outperforming the S&P 500 by 400 basis points annually since 2013, despite recent market challenges. Going forward, I plan on adding to cyclical holdings and expanding my real estate exposure while maintaining my long-term investment strategy.

My Improved Six-Figure Market-Beating Dividend Growth Portfolio

News for AbbVie Stock (ABBV)